<DOC>
	<DOCNO>NCT01519921</DOCNO>
	<brief_summary>This study evaluate efficacy safety PEGASYS ( peginterferon alfa-2a ) patient HBeAg positive chronic hepatitis B . Patients stratify group A ( treatment na√Øve patient ) B ( YMDD mutant patient ) . All patient receive PEGASYS 180 microgram subcutaneously weekly 48 week , follow 24 week treatment-free follow .</brief_summary>
	<brief_title>A Study PEGASYS ( Peginterferon Alfa-2a ( 40KD ) ) Patients With HBeAg Positive Chronic Hepatitis B .</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Adult patient , 1865 year age HBsAg +ve 6 month , HBeAg +ve , AntiHBs Detectable hepatitis B virus ( HBV ) DNA ( &gt; 100,000 copies/mL ) Coinfection hepatitis A , hepatitis C human immunodeficiency virus ( HIV ) Evidence decompensated liver disease A medical condition associate chronic liver disease viral hepatitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>